Prophylactic and therapeutic efficacy of monoclonal antibodies against H5N1 influenza virus - PubMed
5 hours ago
- #monoclonal antibodies
- #pandemic preparedness
- #H5N1
- Monoclonal antibodies (mAbs) show efficacy against H5N1 influenza virus in animal models.
- mAbs target conserved hemagglutinin epitopes, neuraminidase, M2 ectodomain, and nucleoprotein.
- Notable mAbs like CR9114, CR6261, MEDI8852, and TCN-032 have broad neutralizing capabilities.
- Clinical trials for some mAbs showed safety and no resistance emergence but were discontinued.
- Integration of mAbs into H5N1 pandemic preparedness is recommended for early outbreak response.
- Future efforts should address regulatory, logistical barriers, and stockpiling for rapid deployment.